Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study suggests that a low daily dose of finasteride may be effective in reducing recurrent priapism episodes in children and adolescents with sickle cell disease, though larger controlled studies are needed to confirm these findings.

This systematic review found that treatments for sickle cell disease-related priapism are clinically diverse, with etilefrine, pseudoephedrine/etilefrine-5 inhibitors, and finasteride appearing promising, but further research with robust study designs is needed to establish evidence-based practices.

In this case report, a patient with end stage renal disease and sickle cell trait experienced recurrent priapism episodes after starting oral minoxidil for hypertension, which resolved after discontinuing the medication, suggesting minoxidil as a potential trigger in susceptible individuals.

This study found that finasteride may decrease and control the frequency of priapism episodes in patients with sickle cell anemia, with fewer side effects compared to other treatments.

This review discusses the management options for recurrent ischemic priapism, noting that ketoconazole, finasteride, and other hormonal therapies may be effective but can have significant side effects; it reports no new clinical findings.

Finasteride may help treat recurrent priapism in children, but more research is needed.

This article discusses a novel approach to treating recurrent priapism in sickle cell anemia using Finasteride, but provides no new clinical findings.

In this case report, goserelin, a GnRH agonist, was effective in managing stuttering priapism and improving erectile function in a patient with sickle cell disease, suggesting potential for last-line treatment.

This study found that daily finasteride use appears to reduce the frequency of recurrent priapism in children and adolescents with sickle cell disease, with no side effects observed during a short-term follow-up.

In this case report, botulinum neurotoxin injections were associated with a 6-month cessation of priapism episodes in a young man with recurring low-flow priapism, following unsuccessful conventional treatments.

Finasteride may be a promising treatment for recurrent priapism in sickle cell anemia.

This review focuses on recent advancements in understanding and treating ischemic and nonischemic priapism, but does not present new clinical results.

This study reviews three years of experience using Finasteride to treat recurrent priapism in sickle cell anemia and reports no new research findings.

This research suggests that the drugs trazodone and chlorpromazine, which have effects on specific receptors, may help restore libido synaptic circuits and potentially treat sexual dysfunction associated with post-SSRI and post-finasteride syndromes.

This review discusses the management of recurrent ischemic priapism, highlighting that various treatments show differing efficacy and side effect profiles but that more research is needed to refine these strategies.

In this study, the authors propose that drugs like trazodone and antipsychotics such as chlorpromazine, which can induce priapism, may help restore libido synaptic circuits, offering potential treatment for post-finasteride syndrome and post-SSRI sexual dysfunction.

Different medications can cause serious side effects in some people.

This study explored the relationship between BMI percentiles and clinical severity in pediatric patients with different hemoglobin genotypes, finding significant BMI differences and associations with pain frequency, particularly noting that patients with HbSS experienced more pain than those with HbSC.

This study proposes that combining trazodone and clomiphene citrate could potentially restore libido synaptic circuits and treat post-finasteride syndrome, which involves persistent sexual dysfunction after discontinuing finasteride treatment.

This publication compiles abstracts from the 19th Annual Fall Meeting of the Sexual Medicine Society of North America, highlighting advancements and discussions in various areas of sexual medicine without reporting new research results.

This study found that topically applied minoxidil was more effective than nitroglycerin and placebo in enhancing penile diameter, rigidity, and arterial flow, with the most pronounced effects in patients with neurogenic impotence.

This study found that topical application of 2% minoxidil solution was not effective in improving erectile dysfunction in the majority of participants.

This article examines 5 alpha-reductase inhibitors and their link to persistent sexual dysfunction, but it reports no new clinical findings.

The researchers proposed that an epigenetic change in brain androgen receptors caused by finasteride could lead to post finasteride syndrome, while trazodone might reverse this effect by altering the epigenetic expression related to erection and libido.

This study reported that enoxaparin may cause alopecia in patients treated for cerebral venous thrombosis, with hair growth resuming naturally after the treatment ended.

This review discusses the neurobiology of sexual function and reports no new results; the authors cover multiple endocrine and neurotransmitter influences on sexual desire, arousal, and orgasm stages.